1 helper T (T H ) cells specialized in providing help to B cells. They are characterized by their unique transcriptional profile (Bcl6), surface marker expression (CXCR5, PD-1, ICOS and CD40L) and cytokine production pattern (IL-21 and IL-6). T FH cells provide help to B cells both to form germinal centers (GCs) and to differentiate into memory B cells and plasma cells for generation of humoral responses. However, there is emerging evidence that implicates T FH cells in the development of various human pathologies, such as autoimmune diseases, immunodeficiency and lymphoma. This review focuses on the current progress in this area including mouse and human studies. A clearer understanding of the mechanisms of T FH cell-mediated immunity and pathology may be exploited for rational development of therapeutic strategies.
INTRODUCTION
Antibody responses are a key component of the adaptive immune system. These responses are mostly dependent on help from antigen-specific CD4 1 helper T (T H ) cells. In recent years, follicular helper T (T FH ) cells, a specialized subset of T H cells, have attracted much attention due to their ability to provide critical help to germinal center (GC) B cells. Although T FH and other T H cell subsets share many phenotypic and functional features, the recent identification of the master transcriptional regulator, B-cell lymphoma-6 (Bcl6), of T FHcell differentiation has established T FH cells as a distinct subset of T H cells. [1] [2] [3] T FH cells provide help to B cells both to generate and maintain the GCs as well as to differentiate into memory B cells and plasma cells. The plasma cells secrete antigen-specific antibodies for generation of humoral responses against a variety of pathogens, including viruses and bacteria. 4, 5 However, if T FH -cell function is not properly regulated, various pathologies ensue. [6] [7] [8] [9] [10] [11] Here we present a review of the current literature pertaining to the role of T FH cells in the development of pathologies, such as autoimmunity, immunodeficiency and lymphoma, and the implications of these studies for development of therapies.
CHARACTERISTICS OF T FH CELLS
Phenotypically, T FH cells can be characterized by the high expression of certain surface markers, such as chemokine receptor-5 (CXCR5), programmed death-1 (PD-1), inducible costimulator (ICOS) and CD40 ligand (CD40L). 12 These markers contribute to the migration of T FH cells and the interaction of T FH cells with B cells to promote Bcell responses against pathogens. The binding of CXCR5 on T FH cells with its cognate ligand, CXCL-13, in GC facilitates the migration of T FH cells to B-cell follicles for their interaction with B cells. 13, 14 Upon T FH -cell activation, PD-1 induces an inhibitory signal to T FH cells, whereas ICOS functions as a costimulatory molecule, thus determining the outcome of the T FH cell-mediated B-cell response. 15, 16 Furthermore, CD40L, a member of the tumor necrosis factor family, is expressed on activated T FH cells, and its interaction with CD40 on B cells is crucial for immunoglobulin isotype switching. 17 In addition, signaling lymphocytic activation molecule-associated protein (SAP) has been shown to play a critical role for T FH -cell function in GC formation and immune homoeostasis. 18 Cytokines particularly IL-21 and IL-6 have been shown to play a key role in both T FH -cell differentiation and antigen-specific humoral responses. On the one hand, IL-21 has been considered as the master cytokine for the regulation of T FH -cell development that depends on the costimulation via CD40-CD40L and ICOS-ICOSL interactions. IL-21 induces production of IL-21 by T FH cells in an autocrine fashion, leading to the differentiation of T FH cells. 19 Furthermore, IL-6 induces both IL-21 production as well as T FH -cell generation. 20 A recent study by Eto et al. 21 shows that T FH -cell differentiation requires both IL-6 and IL-21, and that these cytokines alone are not sufficient to drive T FH -cell differentiation, indicating the synergistic relationship between IL-21 and IL-6 that regulates the T FH -cell differentiation. On the other hand, IL-21 is critical for T FH cells to promote B-cell somatic hypermutation and immunoglobulin class switching. 22 T FH cells can also produce other cytokines, similar to other T H cells such as T H1 and T H2 cells, which may be relevant to the development of various classes of antibodies.
The identification of Bcl6 as a master regulator of T FH -cell differentiation has laid the basis for T FH cells as a distinct subset of T H cells.
In contrast to the other T H cell subsets, such as T H 1, T H 2 and T H 17  cells, which are controlled by T-bet, GATA3 and RORct, respectively,  T FH cells are dependent on Bcl6. 1-3 Bcl6-deficient mice failed to develop T FH cells, suggesting that Bcl6 is critical for programming of T FH -cell differentiation. [1] [2] [3] In contrast, Blimp-1, another transcription factor, acts as an antagonist of Bcl6 by specifically inhibiting T FH -cell differentiation. 23 Therefore, Bcl6 and Blimp-1 are critical for T FH -cell differentiation, with promoting and regulatory role, respectively.
Although T FH cells act as a distinct subset of T H cells, they also show considerable plasticity. T FH cell-like features can also be exhibited by other subsets of T cells, including regulatory T (T reg ) and invariant natural killer T (iNKT) cells. [24] [25] [26] [27] In particular, recent studies have described a population of follicular T regulatory (T FR ) cells that share the phenotypic characteristics with T FH and T reg cells. Like classic T FH cells, the so-called T FR cells express high levels of CXCR5 and PD-1, and require Bcl6, SAP and CD28 for their development, but they express Foxp3 and can inhibit the GC reactions, similar to T reg cells. T FR cells are considered to be produced de novo from the progenitors of CXCR5
2 Foxp3 natural T reg cells. [25] [26] [27] Interestingly, the expression of T FH cell-like phenotype is not just confined to conventional T cells. Chang et al. 24 recently identified a subset of iNKT, iNKT FH , cells that share phenotypic, functional and ontological characteristics of T FH cells. These iNKT FH cells showed enhanced expression of CXCR5 and PD-1, and provided help to lipid antigen-reactive B cells via production of IL-21. Not surprisingly, the development of iNKT FH cells was found to be dependent on the transcriptional factor Bcl6 and CD28 signaling. 24 
T FH CELLS IN AUTOIMMUNITY
The hallmark of T FH -cell function is to help B cells to generate humoral immune responses, which is a complex physiological process that requires the formation of GC in secondary lymphoid tissues, such as spleen and lymph nodes. Specifically, T FH cells emit instructive signals to B cells to form and maintain GC. The GC provides a podium where T FH cells instruct B cells not only to differentiate into memory B cells, but also to class switch for antibodies through somatic hypermutation and isotype switching, resulting in the formation of antigen-specific high-affinity antibodies to combat infectious agents. 28 However, unwanted antibody responses can come with the risk of autoimmune diseases ( Figure 1 ). Many lupus-prone murine models show the spontaneous generation of GCs that is positively correlated with the production of autoantibodies. 29, 30 In human systemic lupus erythematosus (SLE) patients, autoreactive B cells actively participate in GC reactions, which eventually lead to the formation of pathogenic autoantibodies. 31 A growing body of evidence further suggests that the aberrant function of T FH cells plays a critical role in generation of autoantibodies via autoreactive GC B cells, which inflict autoimmune pathologies in humans and mice (Table 1) .
T FH cells in murine models of autoimmune diseases
The contribution of T FH cells in autoimmune diseases has been mainly studied in murine models of SLE. Most data supporting the role of T FH cells in murine lupus come from studies using sanroque mouse model. Sanroque mice are having a single recessive mutation in the roquin gene that encodes a highly conserved protein, a member of the RINGtype ubiquitin ligase protein family. These mice exhibit SLE-like pathologies, such as high-affinity anti-dsDNA antibodies, focal proliferative glomerulonephritis, necrotizing hepatitis, anemia and autoimmune thrombocytopenia. The sanroque mutation not only causes the formation of excessive T FH cells and GCs, but also disrupts a repressor of ICOS and results in aberrant production of IL-21. 6 Using sanroque mice, Linterman et al. 32 recently investigated the role of T FH cells in the development of murine lupus. They found that deletion of an allele of Bcl6 reduced the number of GC cells and ameliorated the SLE-like pathological reactions, suggesting that autoimmunity in sanroque mice is largely dependent on GC. Furthermore, they found that deficiency of SAP in sanroque mice resulted in a significant reduction in T FH cells and IL-21, and abrogated GC formation, autoantibody production and renal pathology. More convincingly, adoptive transfer of sanroque T FH cells into wild-type recipient mice led to the spontaneous GC formation that resulted in pathology, confirming the direct involvement of T FH cells in the pathogenesis of the lupus-like diseases. 32 Overall, these data suggest that dysregulation of the GC response through excessive formation of T FH cells is responsible for autoimmunity in sanroque mice. However, some studies showed that roquin represses autoimmunity by limiting ICOS mRNA expression through a microRNA-independent posttranslational repression. 33, 34 In addition, a recent study showed that the loss of roquin induced early death and immune dysregulation but not autoimmunity in sanroque mice. 35 Therefore, future studies are required to completely elucidate the mechanisms behind pathogenesis of lupus in sanroque mice.
T H -cell differentiation is polarized toward T FH cells to generate B-cell responses against infections. 36, 37 These responses, if exaggerated by aberrant T FH -cell function, may also promote autoimmune diseases. A recent interesting study examined the role of T FH cells in the development of autoimmunity during chronic Salmonella infection in mice. The study showed that mice deficient in MyD88 when challenged with recombinant-attenuated Salmonella enterica serovar Typhimurium vaccine strain resulted in chronic infection, which was subsequently followed by the development of autoimmune pathologies, such as autoimmune hypergammaglobulinemia and deposition of immune complexes in the kidneys. In these mice, a population of T FH cell-like cells expressing the higher levels of PD-1, CXCR5, ICOS and IL-21 was found to be significantly expanding compared with healthy controls. In addition, blocking the function of these cells by anti-ICOS or anti-PD-1 antibodies ameliorated hyper-IgG in recombinant-attenuated Salmonella enterica serovar Typhimurium vaccine-infected MyD88-deficient mice. These observations suggest that the overrepresentation of T FH -like cells in chronic bacterial infection elicits autoimmune pathologies in a PD-1-and ICOS-dependent fashion. 38 Aberrant production of T FH cell-associated cytokines, particularly IL-21 has been shown to be critical for the development of autoimmunity in lupus-prone mice. IL-21 is mainly produced by T FH cells and appears to be crucial for T FH -cell differentiation and GC reactions. 18, 39, 40 Several studies using lupus-prone mouse models have provided strong evidence for the involvement of IL-21 in autoimmunity. Ozaki et al. 41 showed that BXSB-Yaa mice, which reveal features of lupus, had overexpansion of T FH cells and excessive production of IL-21. Additionally, blocking IL-21 in the lupus-prone MRL lpr mice led to reduced lupus pathologies, such as pathogenic autoantibodies, lymphadenopathy and deposition of immune complexes in the kidney. 42 Consistently, when MLR lpr mice were made deficient in IL-21R, they showed reduced splenomegaly, lymphadenopathy and autoantibody production, and lacked spontaneous GC formation and plasmacell accumulation. 43 Moreover, the role of IL-21 is also shown in another model of murine lupus, NZB/W F1 mice, which exhibit clinical features that resemble those of human SLE, including autoantibody production and immune complex-mediated nephritis. 44, 45 Upon intranasal administration of anti-CD3 antibodies, NZB/W F1 mice exhibited suppressed lupus development characterized by reduced levels of autoantibodies and diminished glomerulonephritis. 45 It was found that the treatment with anti-CD3 antibody affected the function of CD4
1 CXCR5 1 ICOS 1 T FH cells, characterized by decreased IL-21 and IL-17 production in these mice which was associated with the autoimmune pathologies. 45 Moreover, a recent in vivo study found IL-27 to be crucial for promoting autoimmune pathologies through inducing the production of IL-21 by T FH cells in a murine model of pristane-induced lupus. 46 Using IL-27a-receptor-deficient (IL-27Ra 2/2 ) mice, Batten et al. 46 showed that IL-27 is important for 
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IL-21 production and T FH -cell survival. They found that mice deficient in IL-27Ra, when treated with pristane, exhibited diminished autoantibody production and mild renal lesions compared with pristane-treated wild-type mice.
The identification of T FR cells has further deepened our understanding of how overexpansion of GC is prevented from autoantibody production. [25] [26] [27] 47 Lim et al. 47 first reported that T FR cells migrate to follicles in human tonsils and elicit suppressive effect on the T FH cell-mediated B-cell responses, such as antibody production, B-cell survival and expression of activation-induced cytosine deaminase. In vivo studies in mice have further provided direct evidence to show a critical role for T FR cells in inhibiting the GC responses. [25] [26] [27] T FH cells in human autoimmune diseases Although less clearer than that in murine models, the implications of T FH cells in the development of human autoimmune diseases have started to be appreciated. 6, 32 Earlier studies have provided indirect evidence to indicate the role of T FH cells in promoting human autoimmunity, e.g., production of pathogenic autoantibodies in SLE patients caused by dysregulated GC reactions, 31, 48 presence of the aggregates of T and B cells containing plasmablasts in the kidneys of patients with lupus nephritis 49 and reduced GC reactions upon blocking CD40L-CD40 interactions in patients with active SLE. 50 Recent studies have further provided clearer evidence on the role of T FH cells in promotion of both systemic and organ-specific autoimmune diseases in humans. [51] [52] [53] [54] [55] Simpson et al. 51 performed an elegant study investigating the role of T FH cells in patients with SLE and Sjogren's syndrome. They found an overrepresented population of CD4
1

CXCR5
1 T FH cell-like cells in the blood, referred to as circulating T FH (T FHC ) cells, of a subset of the SLE patients (14 out of 46), which expressed ICOS and PD-1 compared with healthy controls. Furthermore, the expansion of T FHC cells was found to be positively correlated with severity of the SLE as evidenced by high autoantibody titer, glomerulonephritis and thrombocytopenia that resulted in endorgan damages. The alteration of T FHC cells has been reported in patients with various autoimmune diseases, such as rheumatoid arthritis, primary Sjogren's syndrome, juvenile dermatomyositis and autoimmune thyroid diseases, where T FHC cells are present at a higher frequency and show positive correlation with serum autoantibody titer in the patients. [52] [53] [54] [55] Overall, these observations suggest an important role for T FHC cells in human autoimmunity. However, it should be noted that although T FHC cells resemble T FH cells in terms of ICOS and PD-1 expression, T FHC cells in SLE patients do not express Bcl6 and IL-21 that are hallmarks of classic T FH cells. 51 This discrepancy poses a pertinent question as to whether T FHC and T FH cells are indeed related. It may be that T FHC cells are a subset of T FH cells residing in the lymphoid organs that may downregulate Bcl6 while migrating to the systemic circulation as T FHC cells. This is in accordance with the fact that T FH cells may downregulate Bcl6 over weeks after antigenic challenge. 56 Recently, Morita et al. 52 shed light on the relationship between T FHC (CD4 Evidence from other recent studies also points toward a relationship between T FHC and T FH cells. The patients deficient in ICOS and CD40L lack T FHC cells, whereas T FHC cells expressing ICOS are overrepresented in SLE and rheumatoid arthritis patients. 10, 51, 53 T FH CELLS AND IMMUNODEFICIENCY Immunodeficiency is a pathological condition where the immune response is compromised or absent. Defects in humoural immune response lead to the humoral immunodeficiencies, such as common variable immunodeficiency (CVID), X-linked hyper IgM syndrome (HIGM) and X-linked lymphoproliferative disease (XLP). The clinicopathological presentation of these diseases includes severely impaired humoral immune responses characterized by the absence of GC and altered production of antigen-specific memory B cells and antibodies. 57 The underlying etiology and molecular mechanisms of these diseases remain unclear. Recent studies have, however, implicated various genes such as ICOS, CD40L and SAP to be involved in pathogenesis of the diseases. Deficiency of ICOS or CD19 can cause CVID, whereas SAP deficiency results in XLP. HIGM develops as a result of the absence of CD40L. Mice that are deficient in ICOS, CD40L or SAP reflect clinical features similar to those of patients of the immunodeficiencies. 58 Since ICOS, CD40L and SAP are highly expressed by T H cells, especially T FH cells, and that mutations in them can lead to altered development and/or function of T H /T FH cells, it is highly likely that T FH cells play a critical role in humoral immunodeficiencies. Bossaller et al. recently studied the frequencies of CXCR5
1 T FH cells in CVID patients and ICOS-deficient mice and found that CXCR5
1 T FH cells were severely reduced in the peripheral blood of CVID patients compared with healthy individuals. Consistently, ICOS-deficient mice were significantly depleted of CXCR5
1 T FH cells in the blood and lymphoid tissues, and that the lack of GC was associated with reduced numbers of CXCR5
1 T FH cells in B-cell follicles. 10 Furthermore, deletions of CD19 can also cause CVID, which is characterized by defective B-cell responses and lack of T FH cells. 59 Similar to these findings, individuals suffering from XLP and SAP-deficient mice also exhibit severely impaired B-cell responses with altered development and/or function of T FH cells. 60 Ma et al. showed that XLP patients had reduced numbers of CD4 1 T cells compared with healthy individuals. The CD4 1 T cells produced lower quantities of IL-10 and failed to provide help for B-cell responses. 61 Similarly, mice deficient in SAP show severe functional defects in CD4
1 T cells as evidenced by their inability to confer long-lived humoral responses. 62 Studies further demonstrate that CD4
1 T-cell function in HIGM patients, which lack CD40L, is strictly compromised.
63
T FH CELLS AND LYMPHOMA Emerging evidence supports the relationship between T FH cells and lymphoma, particularly peripheral T-cell lymphoma (PTCL). PTCLs are a rare family of lymphomas with unfavorable prognosis. They may be classified into three types, anaplastic large-cell lymphoma, angioimmunoblastic T-cell lymphoma (AITL) and unspecified PTCL. AITL is the most widely studied type of PTCL, and thus considered as the prototype of T-cell lymphoma. Recent studies have suggested that T FH cells and neoplastic AITL cells share the expression of many phenotypic markers, and that the AITL cells may be derived from T FH cells. [64] [65] [66] [67] [68] Examples of these markers expressed by both T FH cells and neoplastic AITL cells include Bcl6, CXCR5, PD-1, CD40L, OX40 and CXCL13. However, neoplastic AITL cells, in contrast to T FH cells, express CD10, which is a cell surface zinc metalloendopeptidase expressed in a variety of normal and neoplastic tissues. Thus, CD10 may be used as a phenotypic marker to distinguish neoplastic AITL 70 showed an atypical subset of primary cutaneous small/medium-sized pleomorphic CD4
1 T-cell lymphomas, which not only expressed T FH cell markers, such as PD-1, CXCL13 and Bcl6, but also localized in vicinity of B cells, leading to the formation of clusters. Although these data support the derivation of the AITL cells from T FH cells, the underlying molecular mechanism for neoplastic transformation of T FH cells into AITL and primary cutaneous small/ medium-sized pleomorphic CD4
1 T-cell lymphomas remains obscure. Since T FH cells are critical constituents of the micromilieu of B-cell lymphoma, and can influence the development of neoplastic B cells, they are likely to have an important role in development of B-cell lymphoma. This concept is supported by a recent study which described a population of T FH cell-like cells in the vicinity of follicular lymphoma that develops from GC B cells. 2 T cells. In contrary to T FH cells, the gene profiling of these cells showed that they expressed many genes, tumor necrosis factor, LTA, IL-4 and CD40LG, which are involved in the process of lymphoma development. 71 
CONCLUDING REMARKS
In recent years, significant advances have been made in understanding the immunobiology of T FH cells and relevance of these cells with various diseases. T FH cells have surfaced as a distinct subset of T H cells that provide help to B cells, and play a critical role in generation and maintenance of humoroul immune responses. Emerging evidence also illustrates that the aberrations in T FH function may lead to development of a variety of pathologies, such as autoimmune diseases, immunodeficiencies and lymphomas. A better understanding of the role of T FH cells both in protective immunity and pathology is crucial for designing specific therapies for pathologies like autoimmune diseases and immunodeficiencies. For example, T FH cell-associated molecules, such as PD-1, ICOS and CD40L may be interesting targets for treating autoimmunity and immunodeficiency. Suppressing the expression of these molecules may contain autoimmune responses, whereas promoting their expression may ameliorate immunodeficiency. Specifically, further studies are required to answer important mechanistic questions behind the T FH cell-mediated development of pathologies and to address the potential to target T FH cells:
1. What is the basis for the aberrations in T FH -cell function and the subsequent development of pathologies in autoimmunity and immunodeficiency in the mouse models and patients? 2. What is the role of T FR cells in controlling autoimmune diseases and what approaches can be taken to promote the role of these cells? 3. HowtotranslatetheknowledgeonT FH cellsgainedfrommousemodel studiesintohumanautoimmunediseasesandisitpossibleforcirculating T FHC cells to be a biomarker in disease diagnosis and treatment?
